I2GROW INNOVATION TO GROW SRL

Their core work

I2GROW is a Milano-based innovation SME specialising in digital health solutions that use machine learning and IoT to improve patient outcomes outside traditional clinical settings. Their work focuses on building predictive models from real-world data — identifying early signs of cognitive decline and managing chronic conditions like heart failure through continuous remote monitoring. They bring a data engineering and applied AI perspective to clinical research consortia, translating raw patient data streams into actionable intervention triggers. In practice, they are the technology bridge between medical research and deployable digital health products.

What they specialise in

How they've shifted over time

I2GROW entered H2020 in 2021 with both projects starting simultaneously, so a true chronological evolution is limited — but the thematic contrast between the two projects reveals a clear dual specialisation: one track rooted in neuroscience-adjacent prediction (cognitive decline, dementia) and one in chronic disease management via connected devices (heart failure, IoMT). The more technically dense keyword set sits in the RETENTION project, suggesting their capabilities evolved or expanded toward IoT infrastructure and big data pipelines as that project ramped up. The direction is toward richer real-time data ecosystems rather than static prediction models alone.

I2GROW is moving toward full-stack connected health platforms — combining IoT device integration, real-world data pipelines, and ML-driven clinical decision support — positioning themselves as end-to-end digital health solution providers rather than pure analytics specialists.

How they like to work

I2GROW participates exclusively as a consortium member, never as coordinator — consistent with an SME that contributes specialised technology capability rather than leading large multi-partner programmes. Their two projects involve 28 unique partners across 15 countries, which is substantial for just two RIA grants and suggests they are embedded in well-connected, multidisciplinary consortia. This indicates they are sought out for specific technical contributions (AI, IoMT, data engineering) and are comfortable operating within complex international team structures.

Despite only two projects, I2GROW has built connections with 28 distinct consortium partners across 15 countries — a wide European footprint for a small SME. Their network spans the Health pillar specifically, meaning their contacts are primarily in clinical research institutions, health technology companies, and medical faculties across Europe.

What sets them apart

I2GROW occupies a precise niche: applied AI and connected health engineering for chronic and neurodegenerative disease management, delivered by a lean SME that can move faster than a research institute but carries more technical depth than a generic IT consultancy. Their simultaneous presence in both cognitive health (LETHE) and cardiology remote monitoring (RETENTION) makes them unusually versatile across disease areas that typically sit in separate research silos. For a consortium needing a technology partner who understands both the clinical data context and the engineering of real-world deployment, I2GROW is a strong fit.

Highlights from their portfolio

• RETENTION
  The largest of their two grants (EUR 288,706 is actually LETHE — RETENTION at EUR 202,600 runs to 2026), RETENTION is notable for combining IoMT infrastructure, big data pipelines, and ML-driven intervention in a single heart failure management platform deployed outside hospital walls.
• LETHE
  Their highest-funded project (EUR 288,706), LETHE targets one of the most commercially significant unmet needs in healthcare — early, personalised detection of dementia risk — using lifestyle data and prediction models rather than expensive clinical diagnostics.